D. DO NOT COMPLY WITH PERFORMANCE STANDARDS; ARE HELD AND WILL REMAIN UNDER BOND; AND WILL NOT BE. INTRODUCED INTO COMMERCE UNTIL NOTIFICATION IS RECEIVED FROM FDA THAT PRODUCTS HAVE BEEN BROUGHT. INTO COMPLIANCE IN ACCORDANCE WITH AN FDA APPROVED PETITION.
HHMI researchers identify gene mutations that cause a potentially fatal clotting disorder. Researchers have determined the cause of a potentially deadly inherited blood-clotting disorder that can lead to kidney failure or stroke. The researchers found that the disorder, thrombotic thrombocytopenic purpura (TTP), is caused by mutations in a gene that render the ADAMTS13 enzyme ineffective.
other disorders-associated with the TTR gene. In elderly people, deposits of transthyretin protein cause a condition called senile systemic amyloidosis. People with this condition do not have a mutation in the TTR gene; for reasons that are unclear, the transthyretin protein abnormally begins to form protein deposits.